Why the study?
A fraction of pediatric respiratory infections remain unexplained despite advanced PCR-based assays, accompanied by a perception that novel viruses may be present.
Does target-independent high-throughput sequencing improve the detection of viral pathogens in pediatric patients with unexplained respiratory infections?
Does target-independent high-throughput sequencing improve the detection of viral pathogens in pediatric patients with unexplained respiratory infections?
Target-independent high-throughput sequencing can resolve over 50% of unexplained pediatric respiratory infections, primarily by identifying known rather than novel viral pathogens.
Known viruses explain most PCR-negative pediatric respiratory cases; leaves open whether novel pathogens drive the minority of truly unexplained infections.
Despite the advanced PCR-based assays available, a fraction of the pediatric respiratory infections remain unexplained every epidemic season, and there is a perception that novel viruses might be present in these specimens. We systematically collected samples from a prospective cohort of pediatric patients with respiratory infections, that returned negative results by validated molecular RT-PCR assays, and studied them with a target-independent, high-throughput sequencing-based approach. We also included a matched cohort of children with no symptoms of respiratory infection, as a contrast study population. More than fifty percent of the specimens from the group of patients with unexplained respiratory infections were resolved. However, the higher rate of detection was not due to the presence of novel viruses, but to the identification of well-known viral respiratory pathogens. Our results show that already known viral pathogens are responsible for the majority of cases that remain unexplained after the epidemic season. High-throughput sequencing approaches that use pathogen-specific probes are easier to standardize because they ensure reproducible library enrichment and sequencing. In consequence, these techniques might be desirable from a regulatory standpoint for diagnostic laboratories seeking to benefit from the many advantages of these sequencing technologies.
No takes yet. Share an insight, caveat, or question.
Pérez‐Sautu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: